Clinical Trials
57 trialsNCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07343960 2026-05-20
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
Phase 1 Recruiting
NCT07287917 2026-05-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02523014 2026-05-08
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06982521 2026-05-08
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT04439123 2026-05-06
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04493853 2026-05-05
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT03660826 2026-05-04
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03616587 2026-04-30
SERENA-1
AstraZeneca
Phase 1 Active not recruiting
NCT04305496 2026-04-30
CAPItello-291
AstraZeneca
Phase 3 Active not recruiting
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03742102 2026-04-24
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07241065 2026-04-15
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
AstraZeneca
Phase 1 Recruiting
NCT06764186 2026-04-08
CAPItana
AstraZeneca
Phase 3 Active not recruiting
NCT05593497 2026-03-27
SNARE
VA Office of Research and Development
Phase 2 Recruiting
NCT06635447 2026-03-27
CAPItrue
AstraZeneca
Phase 3 Active not recruiting
NCT07486648 2026-03-24
Precision
Shanxi Province Cancer Hospital
Phase 1/2 Not yet recruiting
NCT07294677 2026-03-04
CAVALRY
University of Chicago
Phase 1/2 Recruiting
NCT07088913 2026-03-03
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT07281833 2026-02-27
CAPIcorn
West German Study Group
Phase 3 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT03997123 2025-12-22
CAPItello-290
AstraZeneca
Phase 3 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT01992952 2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2 Active not recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06607757 2025-04-02
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
GBG Forschungs GmbH
Phase 2 Recruiting
NCT02423603 2025-03-10
PAKT
Queen Mary University of London
Phase 2 Completed
NCT05348577 2025-01-27
CAPItello280
AstraZeneca
Phase 3 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT05008055 2024-12-20
CAPITAL
AstraZeneca
Phase 2 Completed
NCT02338622 2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT04958226 2024-01-25
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT04742036 2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT04944771 2022-05-09
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT02121639 2022-05-05
ProCAID
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed